Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mickael Guedj

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Arthritis and Rheumatism|April 12, 2011
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysisBaptiste Coustet, Philippe Dieudé, Mickael Guedj, et al.
Genetic Epidemiology|November 30, 2007
Multistage designs in the genomic era: providing balance in complex disease studiesMarie-Pierre Dubé, Silke Schmidt, Elizabeth Hauser, et al.
International Journal of Cancer|October 11, 2014
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predispositionMaider Ibarrola-Villava, Rajiv Kumar, Eduardo Nagore, et al.
The Journal of Rheumatology|March 3, 2011
Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohortsBaptiste Coustet, Sandeep K Agarwal, Pravitt Gourh, et al.
Genetic Epidemiology|November 30, 2007
Multiple testing in the genomics era: findings from Genetic Analysis Workshop 15, Group 15Lisa J Martin, Jessica G Woo, Christy L Avery, et al.
The Journal of Rheumatology|March 17, 2012
Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosisBaptiste Coustet, Matthieu Bouaziz, Philippe Dieudé, et al.
Orphanet Journal of Rare Diseases|December 19, 2014
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AShahram Attarian, Jean-Michel Vallat, Laurent Magy, et al.
Orphanet Journal of Rare Diseases|July 9, 2016
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AShahram Attarian, Jean-Michel Vallat, Laurent Magy, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Arthritis and Rheumatism|April 12, 2011
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysisBaptiste Coustet, Philippe Dieudé, Mickael Guedj, et al.
Genetic Epidemiology|November 30, 2007
Multistage designs in the genomic era: providing balance in complex disease studiesMarie-Pierre Dubé, Silke Schmidt, Elizabeth Hauser, et al.
International Journal of Cancer|October 11, 2014
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predispositionMaider Ibarrola-Villava, Rajiv Kumar, Eduardo Nagore, et al.
The Journal of Rheumatology|March 3, 2011
Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohortsBaptiste Coustet, Sandeep K Agarwal, Pravitt Gourh, et al.
Genetic Epidemiology|November 30, 2007
Multiple testing in the genomics era: findings from Genetic Analysis Workshop 15, Group 15Lisa J Martin, Jessica G Woo, Christy L Avery, et al.
The Journal of Rheumatology|March 17, 2012
Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosisBaptiste Coustet, Matthieu Bouaziz, Philippe Dieudé, et al.
Orphanet Journal of Rare Diseases|December 19, 2014
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AShahram Attarian, Jean-Michel Vallat, Laurent Magy, et al.
Orphanet Journal of Rare Diseases|July 9, 2016
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AShahram Attarian, Jean-Michel Vallat, Laurent Magy, et al.
Pageof 3